Primary Site >> Colorectal Cancer
Gene >> ERBB3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Differential expression of epidermal growth factor-related proteins in human colorectal tumors. PMID: 1715580 |
Ref: Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family. PMID: 7478540 |
Ref: ErbB kinases and NDF signaling in human prostate cancer cells. PMID: 9400997 |
Ref: Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. PMID: 9712416 |
Ref: Regulation of cyclooxygenase-2 pathway by HER2 receptor. PMID: 9927187 |
Ref: The role of HER2 in angiogenesis. PMID: 11706393 |
Ref: Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. PMID: 11791178 Ref: Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. PMID: 12008194 |
Ref: Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line. PMID: 12571082 |
Ref: Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. PMID: 15059917 Ref: (99m)Tc-Cys-Gly-Gly-Affibody ZHER2:342 PMID: 20641196 Ref: (111)In-Benzyl-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-ZHER2:342 PMID: 20641264 Ref: BODIPY-FL-neutravidin-biotin-Cetuximab PMID: 20641313 Ref: Trastuzumab-manganese-doped iron oxide nanoparticles PMID: 20641351 Ref: (111)In-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid- Affibody ZHER2:342-pep2 PMID: 20641379 Ref: Cy5.5-Trastuzumab PMID: 20641392 Ref: (111)In-Diethylenetriamine pentaacetic acid-pertuzumab PMID: 20641430 Ref: (111)In-CHX-A"-diethylenepentaacetic acid-Affibody ZHER2:2395-Cys PMID: 20641462 Ref: Trastuzumab-rhodamine green PMID: 20641468 Ref: (111)In-CHX-A"-Diethylenetriamine pentaacetic acid-(ZEGFR:955)2 PMID: 20641502 Ref: (111)In-Benzyl-diethylenetriaminepentaacetic acid-ZHER2:342 PMID: 20641524 Ref: [O-(11)C-methyl]4-N-(3-Bromoanilino)-6,7-dimethoxyquinazoline PMID: 20641571 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-cetuximab PMID: 20641633 Ref: (68)Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-Epidermal growth factor PMID: 20641634 Ref: (111)In-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-AB.Fab4D5 PMID: 20641705 Ref: Quantum dot-trastuzumab PMID: 20641720 Ref: (99m)Tc-Affibody ZHER2:2395-Cys PMID: 20641788 Ref: IRDye 800CW-Epidermal growth factor PMID: 20641801 Ref: (111)In-BZ-Diethylenetriaminepentaacetic acid-ZEGFR:1907 PMID: 20641849 Ref: (177)Lu-Labeled humanized monoclonal antibody against human epidermal growth factor receptor 2 PMID: 20641866 Ref: Cy5.5-Epidermal growth factor PMID: 20641899 Ref: (111)In-1,4,7,10-tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidoethylacetamide-Affibody ZHER2:2395-Cys PMID: 20641906 Ref: (99m)Tc-Mercaptoacetyl-Ser-Ser-Ser-Affibody ZHER2:342 PMID: 20641924 Ref: (99m)Tc-Mercaptoacetyl-Gly-Gly-Gly-Affibody ZHER2:342 PMID: 20641926 Ref: (99m)Tc-Mercaptoacetyl-Glu-Glu-Glu-Affibody ZHER2:342 PMID: 20641930 Ref: (125)I-Labeled anti-epidermal growth factor receptor human Fab antibody fragment PMID: 20642017 Ref: Alexa Fluor 750-ZHER2:342 Affibody PMID: 20662137 Ref: DY-682-Albumin-binding domain-fused-ZHER2:342 Affibody PMID: 20845546 Ref: IRDye 800-Anti-epidermal growth factor receptor Affibody PMID: 20845547 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-panitumumab PMID: 20945561 Ref: (68)Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-synthetic HER2 specific Affibody ZHER2:342-pep2 PMID: 21086574 Ref: (86)Y-CHX-A''-Diethylenetriamine pentaacetic acid-cetuximab PMID: 21086575 Ref: Alexa Fluor 750-albumin-binding domain-fused-(ZHER2:342)2 Affibody PMID: 21491705 Ref: (124)I-Labeled anti-HER2-specific C6.5 diabody PMID: 21834183 Ref: (86)Y-CHX-A''-diethylenetriamine pentaacetic acid-panitumumab PMID: 22171389 Ref: (18)F-1,4,7-Triazacyclononane-1,4,7-triacetic acid-10-maleimidoethylacetamide-Affibody ZHER2:2395 PMID: 22479718 Ref: (89)Zr-Desferrioxamine p-isothiocyanatobenzyl-anti-EGFR nanobody 7D12 PMID: 22696779 Ref: (68)Ga-Desferrioxamine p-isothiocyanatobenzyl-anti-EGFR nanobody 7D12 PMID: 22696780 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid-(Gly-Ser-Gly)-Lys-Cys-Cys-Tyr-Ser-Leu PMID: 22787682 Ref: (64)Cu-Bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-(Gly-Ser-Gly) -Lys-Cys-Cys-Tyr-Ser-Leu PMID: 22787683 Ref: (64)Cu-1,4,7-Triazacyclononane-1,4-diacetic acid-(Gly-Ser-Gly)-Lys-Cys-Cys-Tyr-Ser-Leu PMID: 22787684 Ref: IRDye 800CW-Anti-epidermal growth factor receptor nanobody 7D12 PMID: 22787693 Ref: (99m)Tc(CO)3-Anti-epidermal growth factor receptor nanobody 8B6 PMID: 22787694 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-epidermal growth factor receptor-binding fibronectin domain E13.4.3' PMID: 22896860 Ref: Cy5.5-Ac-Cys-ZEGFR:1907 PMID: 22973578 Ref: [(111)In-1,4,7-Triazacyclononane,1-glutaric acid-4,7-acetic acid-10-maleimidoethylacetamide-Cys(61)]-Affibody ZHER2:2395 PMID: 22993871 Ref: (111)In-2-(4,7,10-Tris(carboxymethyl)-1,4,7,10-tetracyclododecan-1-yl)pentanedioi c acid-Trastuzumab PMID: 22993872 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid-human serum albumin-Ac-Cys-ZEGFR:1907 PMID: 23035309 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidethylacetamide-Ac-Cys-ZEGFR:1907 PMID: 23035311 Ref: QD800-Polyethylene glycol-Cys-ZHER2:342 Affibody PMID: 23101053 Ref: ZHER2:342 Affibody-polyethylene glycol-superparamagnetic iron oxide nanoparticles PMID: 23101054 Ref: N-[2-(4-[(18)F]Fluorobenzamido)ethyl]maleimide-Cys-ZEGFR:1907 PMID: 23136679 Ref: (177)Lu-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid-human serum albumin-Ac-Cys-ZEGFR:1907 PMID: 23166961 Ref: Cy5.5-8-Amino-octanoic acid-Ser-Cys-Pro-Pro-Trp-Gln-Glu-Trp-His-Asn-Phe-Met-Pro-Phe-NH2 PMID: 23166962 Ref: (68)Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-HER2-specific Affibody ZHER2:2891 PMID: 23256220 Ref: N(epsilon)-(3-[(131)I]Iodobenzoyl)-Lys(5)-N(alpha)-maleimido-Gly(1)-GEEEK-anti-HE R2 nanobody 5F7GGC PMID: 23556153 Ref: QD800-Anti-epidermal growth factor receptor monoclonal antibody nanoparticles PMID: 23586108 Ref: IRDye 800-albumin-binding domain-fused-ZHER2:342 Affibody PMID: 23785735 |
Ref: Listeria monocytogenes produces a pro-invasive factor that signals via ErbB2/ErbB3 heterodimers. PMID: 15480783 Ref: H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. PMID: 15713896 Ref: Quercetin decreases the expression of ErbB2 and ErbB3 proteins in HT-29 human colon cancer cells. PMID: 15741050 Ref: Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. PMID: 15841378 Ref: Reorganization of ErbB family and cell survival signaling after Knock-down of ErbB2 in colon cancer cells. PMID: 15888451 Ref: HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. PMID: 15899817 Ref: Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. PMID: 15908515 Ref: EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. PMID: 16053920 Ref: Trans-10,cis-12, not cis-9,trans-11, conjugated linoleic acid decreases ErbB3 expression in HT-29 human colon cancer cells. PMID: 16127743 Ref: Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of Genistein. PMID: 16379552 Ref: EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. PMID: 16416603 |
Ref: Somatic mutations of the ERBB4 kinase domain in human cancers. PMID: 16187281 Ref: Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. PMID: 16507107 Ref: Mutation of the PI3' kinase gene in a human colon carcinoma cell line, HCC2998. PMID: 16848681 Ref: Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. PMID: 17189393 |
Ref: Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells. PMID: 18948598 |
Ref: Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines. PMID: 19331154 Ref: Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization. PMID: 19368728 Ref: ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. PMID: 19390858 Ref: ErbB 1-4 expression alterations in primary colorectal cancers and their corresponding metastases. PMID: 19443355 Ref: Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. PMID: 19690388 Ref: Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer. PMID: 19797898 Ref: Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant {beta}-Catenin Activation in Colon Cancer. PMID: 20008853 Ref: Human cancer protein-protein interaction network: a structural perspective. PMID: 20011507 |
Ref: The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition. PMID: 19876926 Ref: Tephrosin induces internalization and degradation of EGFR and ErbB2 in HT-29 human colon cancer cells. PMID: 20056314 Ref: Mechanisms of resistance to HER family targeting antibodies. PMID: 20064507 Ref: Significance of integrin alphavbeta5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin. PMID: 20626753 Ref: The EGFR R521K polymorphism influences the risk to develop colorectal cancer. PMID: 21896992 |
Ref: EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer. PMID: 20824716 Ref: HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. PMID: 21098338 Ref: EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. PMID: 21109951 Ref: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. PMID: 21900593 |
Ref: Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. PMID: 22142822 Ref: Increasing potential of HER3 signaling in colon cancer progression and therapy. PMID: 22205688 Ref: ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines. PMID: 22485250 Ref: HER3: a potential marker in colon cancer. PMID: 22550756 Ref: Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. PMID: 22579651 Ref: Recurrent R-spondin fusions in colon cancer. PMID: 22895193 |
Ref: Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. PMID: 22535374 Ref: Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models. PMID: 22973964 Ref: HER3 overexpression and survival in solid tumors: a meta-analysis. PMID: 23221996 Ref: miR-214 and hypoxia down-regulate Necl-2/CADM1 and enhance ErbB2/ErbB3 signaling. PMID: 23301758 Ref: Involvement of heregulin/HER3 in the primary culture of human urothelial cancer. PMID: 23313199 Ref: Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. PMID: 23316969 Ref: Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation. PMID: 23328545 Ref: Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. PMID: 23365119 Ref: The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. PMID: 24050852 Ref: Multigene assays in metastatic colorectal cancer. PMID: 24158971 Ref: Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK. PMID: 24205104 |
Ref: Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. PMID: 23568716 Ref: The ErbB/HER family of protein-tyrosine kinases and cancer. PMID: 24269963 Ref: HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome. PMID: 24300455 Ref: Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule. PMID: 24622956 Ref: ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. PMID: 24634416 Ref: Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. PMID: 24685132 Ref: Nrdp1 inhibits growth of colorectal cancer cells by nuclear retention of p27. PMID: 24867101 Ref: Mutational and expressional analysis of ERBB3 gene in common solid cancers. PMID: 24909266 Ref: ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. PMID: 24970817 Ref: Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status. PMID: 25090459 Ref: Kaempferol Downregulates Insulin-like Growth Factor-I Receptor and ErbB3 Signaling in HT-29 Human Colon Cancer Cells. PMID: 25337585 Ref: Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. PMID: 25389372 Ref: Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer. PMID: 25416285 Ref: The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. PMID: 25474137 |
Ref: Examination of HER3 targeting in cancer using monoclonal antibodies. PMID: 25564668 Ref: HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver. PMID: 25601452 Ref: HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value. PMID: 25739551 Ref: [Accumulation of p53 protein and overexpression of the HER3 receptor in colorectal cancer]. PMID: 25847737 Ref: Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. PMID: 25993166 Ref: Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. PMID: 26034219 Ref: Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. PMID: 26287187 Ref: ERBB3 Positively Correlates with Intestinal Stem Cell Markers but Marks a Distinct Non Proliferative Cell Population in Colorectal Cancer. PMID: 26367378 Ref: Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. PMID: 26427914 Ref: Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer. PMID: 26569500 Ref: Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical Role. PMID: 26571416 |
Ref: Pertuzumab in gastrointestinal cancer. PMID: 26619359 Ref: HER3 expression is correlated to distally located and low-grade colon cancer. PMID: 26863446 Ref: Downregulation of epidermal growth factor receptor family receptors and ligands in a mutant K-ras group of patients with colorectal cancer. PMID: 26935861 Ref: Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance. PMID: 27017409 Ref: Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling. PMID: 27447549 Ref: Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). PMID: 27465221 Ref: Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer. PMID: 27610130 Ref: Genomic characterization of liver metastases from colorectal cancer patients. PMID: 27662660 Ref: DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up. PMID: 27709558 Ref: The prospect of patritumab for treating non-small cell lung cancer. PMID: 27744717 Ref: Down-regulation of microRNA-143 is associated with colorectal cancer progression. PMID: 27906435 Ref: Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot study. PMID: 28050146 |
Ref: KITENIN functions as a fine regulator of ErbB4 expression level in colorectal cancer via protection of ErbB4 from E3-ligase Nrdp1-mediated degradation. PMID: 27648936 Ref: A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan. PMID: 27853996 Ref: Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells. PMID: 28032592 Ref: Prophylactic vaccination targeting ERBB3 decreases polyp burden in a mouse model of human colorectal cancer. PMID: 28197371 Ref: Methods of selecting combination therapy for colorectal cancer patients: a patent evaluation of US20160025730A1. PMID: 28366103 Ref: Profiling Differential Responses to Pan-HER Inhibition. PMID: 28373301 Ref: Prognostic significance of HER3 in patients with malignant solid tumors. PMID: 28978022 Ref: Molecular characterization of circulating colorectal tumor cells defines genetic signatures for individualized cancer care. PMID: 28978093 Ref: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. PMID: 29024937 Ref: Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression. PMID: 29039474 Ref: A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer. PMID: 29179520 Ref: Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. PMID: 29312543 |
Ref: Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. PMID: 29075780 Ref: Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. PMID: 29254887 Ref: BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. PMID: 29326440 Ref: Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. PMID: 29338072 Ref: Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer. PMID: 29361822 Ref: Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. PMID: 29413684 Ref: Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methylome alterations. PMID: 29453410 Ref: Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells. PMID: 29541416 Ref: Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancer. PMID: 29662620 Ref: Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. PMID: 29718453 Ref: Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation. PMID: 29928418 Ref: Aneuploidy of chromosome 8 and mutation of circulating tumor cells predict pathologic complete response in the treatment of locally advanced rectal cancer. PMID: 30008877 Ref: Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion. PMID: 30131447 Ref: Association between the overexpression of Her3 and clinical pathology and prognosis of colorectal cancer: A meta-analysis. PMID: 30212974 |